Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
February 9, 2021If Authorized for Use, ZYESAMI™ Would be First Treatment Specifically for Critically Ill Patients with Respiratory Failure
NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF; OTCQB: RLFTF) today reported preliminary results from the Phase 2b/3 trial of ZYESAMI™ (aviptadil, previously RLF-100) in patients...
-
February 9, 2021If Authorized for Use, ZYESAMI™ Would be First Treatment Specifically for Critically Ill Patients with Respiratory Failure
NeuroRx, Inc. today reported preliminary results from their Phase 2b/3 trial of ZYESAMI™ (aviptadil, previously RLF-100) performed in collaboration with Relief Therapeutics Holdings, AG...
-
February 3, 2021
NeuroRx, Inc. today announced initiation of a Phase 2/3 clinical trial investigating the role of inhaled ZYESAMI™ (aviptadil) for the treatment of patients with Severe COVID-19 in partnership...
-
January 11, 2021
NeuroRx, Inc. and RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief"), and the Quantum Leap Healthcare Collaborative ("Quantum Leap") of San Francisco announce that NeuroRx and QLHC...
-
December 30, 2020
NeuroRx, Inc. and RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief") today announced the conclusion of enrollment in the phase 2b/3 trial of ZYESAMI™ (previously RLF-100TM:...
-
December 7, 2020
NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF,OTCQB: RLFTF) ("Relief") today announced that they have met the 165 patient enrollment target agreed with the U.S. Food and Drug...
-
November 24, 2020
NeuroRx, Inc., and Relief AG (SIX: RLF, OTCQB: RLFTF), announce that more than 175 patients with Critical COVID-19 and Respiratory Failure who also have a severe comorbidity have now been entered...
-
November 13, 2020- Observations of rapid recovery noted on chest x-ray and no drug-related Serious Adverse Events reported
NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF, OTCBB:RLFTF) ("Relief") announced that as of today, 150 patients (out of a targeted enrollment of 165) have been enrolled in the ongoing...
-
November 5, 2020
NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF, OTCBB:RLFTF) ("Relief") announced that the independent Data Monitoring Committee (DMC) met yesterday and voted unanimously that NCT...
-
November 4, 2020
NeuroRx, Inc. today announced that it has received a notice of patent allowance from the United States Patent and Trademark Office (USPTO) covering a formulation for the treatment of...
Click here to view our corporate presentation or on the image below